Half of higher-risk myelodysplastic syndrome patients respond to a hypomethylating agent.1

For those who fail one, median survival runs between four and six months, and 28% are alive at a year.2

When a hypomethylating agent stops working, patients need somewhere to go next. Right now they have nowhere.

Please note: Novexis Bio operates in a stealth capacity.

Everything sent here is read by someone working on it. Nothing you send is used for anything but a reply. Privacy statement.